BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Cellectricon Webinar: New Approach Into the Science of Cytoskeletal Disturbances


4/29/2013 11:42:22 AM

Molndal, Sweden – 29 April 2013 – Cellectricon, a leading provider of advanced cell-based screening technologies and services, invites researchers to join a webinar investigating new methods for approaching drug development in the fields of CNS and chronic pain. The webinar, entitled ‘A Novel Approach to Discovery Using Electric Field Stimulation Assays for Cytoskeletal Disturbances’, will be held on Thursday 16th May, 11am-12pm (EDT) and will offer attendees an ideal opportunity to hear first-hand how compound profiling and Cellectricon’s powerful Cellaxess® Elektra platform can advance research in the area. To register for the webinar visit www.cellectricon.com/events.

Detailing real-life examples, the webinar will provide listeners with an insight into electric field stimulation using the Cellaxess Elektra, and the advanced solution it offers for novel, excitable cell-based assays. The speakers - Dr Mattias Karlsson (Chief Technology Officer, Cellectricon) and Dr Paul Karila (Head of Discovery Services, Cellectricon) - will guide listeners through the technology, applications and key principles for successful phenotypic assays in cytoskeletal research. As such, the webinar will be of particular benefit to scientists and clinical development managers looking to enhance assay workflow and protocols in the fields of neurobiology, lead discovery, in vitro screening and translational science, to name a few key areas.

For more information on Cellectricon, or to register for the webinar visit www.cellectricon.com

About Cellectricon

Cellectricon provides state-of-the-art discovery services and enabling technologies to accelerate drug discovery and cell-based research. Our compound profiling services in excitable cells and native tissue provide researchers with decision-making insight into the science of cytoskeletal disturbances, particularly focusing on chronic pain.



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES